Institutional profile: University of Florida Health Personalized Medicine Program.

Pharmacogenomics 2017 Apr 27;18(5):421-426. Epub 2017 Mar 27.

Department of Pharmacotherapy & Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.

The University of Florida (UF) Health Personalized Medicine Program launched in 2012 with CYP2C19 genotyping for clopidogrel response at UF Health Shands Hospital. We have since expanded CYP2C19 genotyping to UF Health Jacksonville and established the infrastructure at UF Health to support clinical implementation for five additional gene-drug pairs: TPMT-thiopurines, IFNL3 (IL28B)-PEG IFN-α-based regimens, CYP2D6-opioids, CYP2D6/CYP2C19-antidepressants and CYP2C19-proton pump inhibitors. We are contributing to the evidence based on outcomes with genotype-guided therapy through pragmatic studies of our clinical implementations. In addition, we have developed a broad array of educational programs for providers, trainees and students that incorporate personal genotype evaluation to enhance participant learning.

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2017-0028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558508PMC
April 2017
48 Reads

Publication Analysis

Top Keywords

florida health
8
health personalized
8
personalized medicine
8
medicine program
8
university florida
8
cyp2c19 genotyping
8
health
5
inhibitors contributing
4
pump inhibitors
4
cyp2c19-proton pump
4
contributing evidence
4
based outcomes
4
genotype-guided therapy
4
outcomes genotype-guided
4
cyp2d6/cyp2c19-antidepressants cyp2c19-proton
4
evidence based
4
cyp2d6-opioids cyp2d6/cyp2c19-antidepressants
4
gene-drug pairs
4
additional gene-drug
4
implementation additional
4

References

(Supplied by CrossRef)

Cavallari LH et al.
Circulation 2015

Similar Publications